Results 31 to 40 of about 740 (167)

Acute Myeloid Leukemia With Plasmacytoid Differentiating Cutaneous Lesions: A Case of Double Identity or Active Transformation. [PDF]

EJHaem
ABSTRACT Introduction Acute myeloid leukemia (AML) with plasmacytoid dendritic cell differentiation (pDC‐AML) is a newly described subtype of leukemia with features resembling blastic plasmacytoid dendritic cell neoplasm (BPDCN). Case Presentation Herein, we present a case of pDC‐AML in which bone marrow findings were best classified as AML, whereas ...
Lee BJ, Griffin SP, Jeyakumar D, Gamayo A, Rezk SA, Naqvi K.   +5 more
europepmc   +2 more sources

Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN.
Dr sugreev Dwivedi Anuj Dwivedi, Dwivedi, Dr sugreev Dwivedi Anuj   +1 more
core   +1 more source

Analysis of Tagraxofusp Activity in AML-Pdc As a Single Agent and in Combination with BCL2 Inhibitors [PDF]

, 2023
peer reviewed Acute myeloid leukemia with increased plasmacytoid dendritic cells (AML-PDC) is a new leukemia recently clarified in the classification of hematological diseases (WHO 2022).
Fredon, Maxime, Belakri, Imane, Roussel, Xavier, Deconinck, Eric, Garnache Ottou, Francine, Brooks, Christopher, Poussard, Margaux, Biichle, Sabeha, Renosi, Florian, Delettre, Fanny, Boichut, Morgane   +10 more
core   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: a short review and update

Dermatology Reports, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm (less than 1% of primary cutaneous lymphomas and acute leukemia) with a highly aggressive clinical course and frequent skin, bone marrow and central nervous system (CNS)
Cesare Massone, Giulia Rivoli, Simona Sola, Emanuele Angelucci   +3 more
doaj   +1 more source

Tagraxofusp in myeloid malignancies

Hematological Oncology, 2023
Abstract Tagraxofusp (or SL‐401) is a recombinant molecule composed of human interleukin‐3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease ...
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Antonino Neri, Annalisa Imovilli, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +10 more
openaire   +3 more sources

CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia. [PDF]

Br J Haematol
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Dreyzin A, Holtzman NG, Bonifant CL.
europepmc   +2 more sources

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Investigative Medicine High Impact Case Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed
Prashanth Ashok Kumar MBBS, Mulham Ombada MBBS, Gayatri Pemmasani MBBS, Ajay Tambe MBBS, Katalin Banki MD, Teresa Gentile MD, PhD   +5 more
doaj   +1 more source

Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]

Int J Mol Sci
: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens.
Galati D, Zanotta S, Florio F, Mele S, De Filippi R, Pinto A.   +5 more
europepmc   +3 more sources

Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia

Human Vaccines & Immunotherapeutics, 2020
The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss, Mary Clark, Joo Y Song, Vinod Pullarkat   +3 more
doaj   +1 more source

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm [PDF]

Blood Advances, 2020
AbstractBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging hematologic malignancy with dismal outcomes. With a median age of ∼70 years, the majority of patients with BPDCN have experienced historically suboptimal responses with intensive chemotherapy regimens.
Naveen Pemmaraju, Marina Konopleva
openaire   +2 more sources